Author Interviews, Brain Injury, Cannabis / 07.05.2024

MedicalResearch.com Interview with: Pamela Maher, PhD Research Professor Cellular Neurobiology Laboratory SALK Institute for Biologic Studies La Jolla California   MedicalResearch.com: What is the background for this study? Response: Several years ago, we tested several different cannabinoids for protection against the oxytosis/ferroptosis regulated cell death pathway and found CBN (cannabinol) to be one of the most effective. While THC (tetrahydrocannabinol) and CBD (cannabidol) were also quite protective, we wanted to pursue non-psychoactive cannabinoids. Since we are interested in maintaining brain function in the context of aging and disease, we thought that a psychoactive compound could be problematic. In addition, there was already a lot of work on CBD, so we thought we could learn more and contribute more to the field by studying CBN. (more…)
Alzheimer's - Dementia, Author Interviews / 05.08.2020

MedicalResearch.com Interview with: Dr. Pamela Maher, PhD Senior Staff Scientist Cellular Neurobiology Laboratory Salk Institute for Biological Studies  Dr. Pamela Maher, is a senior staff scientist in the lab of Salk Professor David Schubert. MedicalResearch.com: What is the background for this study? Response: An estimated 5.2 million Americans over the age of 65 currently suffer from Alzheimer's disease (AD). There are no treatments that prevent, slow down or cure it. Moreover, the number of people suffering from it is expected to grow with the increase in the aging population. To meet this challenge, the NIH has set the ambitious goal of effectively treating AD by 2025. This will require the development of new disease-modifying drugs. Indeed, compared to cancer research, the drug discovery pipelines for AD are very limited. A missing key ingredient that is needed to re-invigorate AD-related drug discovery is new, promising AD drug targets. Our lab is experienced in screening existing (natural) compounds for their protective abilities against several toxicities related to AD. Protective compounds are then further optimized to generate drug candidates with a favorable profile for the treatment of brain diseases. CMS121 is such a compound which is derived from fisetin, a natural product that can be found in many fruits and vegetables such as strawberries, grapes, cucumbers. Fisetin itself is not as potent and does not have the necessary chemical features to reach the brain efficiently. CMS121 is more potent and easily reaches the brain. We had previously shown that CMS121 improves several age-related cognitive dysfunctions.  (more…)